



Share Price*

\$1.03

52-Week Range*

\$0.77-1.78

Market Cap*

\$29.5M

Net Revenue Est. †

\$21 - 22M

*as of 11/26/18

Overview

Interpace Diagnostics is a fully integrated commercial and bioinformatics company that provides clinically useful molecular and related first line diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace's unique molecular tests offer healthcare providers and patients the benefit of early cancer detection and prognostic evaluation and accordingly more selective surgical

and treatment options. The Company has nationwide reimbursement for its products with major healthcare providers like United Healthcare, Cigna, Medicare, Aetna, Blue Cross Blue Shield and more.

**COVERED BY 30
REGIONAL
BLUE
CROSS BLUE
SHIELD PLANS**

Thyroid Products

ThyGenX®/ThyGeNEXT™ and ThyraMIR®

ThyGenX® - Thyroid Oncogene Panel

Highly specific oncogene (mutational) panel that assesses the most common genetic alternations across 8 genes associated with both papillary carcinoma and follicular carcinoma.

ThyGeNEXT™ - Next Generation Mutation Panel

Goes above and beyond ThyGenX® to include numerous additional molecular markers, gene mutations, and RNA fusions. This more comprehensive set of indicators not only identifies malignant and malign nodules, but also ascertains aggressiveness and other characteristics.

ThyraMIR® - Thyroid miRNA Classifier

The first and only miRNA gene expression classifier and is based on the evaluation of the relative expression of 10 miRNAs.

85%
reduction in
unnecessary
surgeries

When used in combination, ThyGenX®/ThyGeNEXT™ and ThyraMIR® offer a 94% NPV, a 74% PPV, and an 85% reduction in unnecessary surgeries. Sensitivity is 89% and Specificity is 85%

275
million lives
covered

Interpace's thyroid tests cover over 275 million lives

20K
thyroid tests
conducted

Over 20,000 molecular thyroid tests performed by over 400 physicians and hospitals nationwide



PancraGEN®

PancraGEN® is a unique, DNA-based integrated molecular pathology test that assesses the risk of pancreatic and bile duct cancer in pancreatic cysts and pancreaticobiliary solid lesions. It is the first and only U.S. commercially available molecular test for pancreatic cancer evaluation.

55,440
estimated new cases of pancreatic cancer in 2018

80%
of surgeries reveal idolent cysts, which don't require surgery

>30,000
tests performed

PancraGEN® has better predictive value for cancer than guidelines and identifies more patients in whom surgery can be avoided

234,030

estimated new cases of lung cancer in 2018

\$13.4 billion

cost of lung cancer care in the U.S. in 2015

RespriDx™

RespriDx™ is a test to determine whether abnormal growths represent metastases or new primary lung cancers.

BarreGEN®

BarreGEN® enables the assessment for the risk of progression from Barrett's Esophagus, a rapidly growing condition, to esophageal cancer, allowing for more personalized management of the disease.

\$1 – \$1.5 billion
market potential in the U.S.

~3.5 million
adults in the U.S. will be diagnosed with Barrett's Esophagus

Financials



Gross profit percentage for 2017 improved to 53.7%, compared to 49.2% in 2016

Cash & cash equivalents on hand at 09/30/2018: \$8.0M with no long-term debt

Revenue for 2017 was \$15.9M representing a 21% increase compared to 2016

Revenue guidance increased for 2018 from \$20 million to range between \$21 - \$22 million

Q2 2018 record quarterly revenue of \$5.5 million

Stockholder's Equity amounted to \$36.0 million as of 09/30/18

Adjusted EBITDA was \$(3.4) million for the nine-month period ended on 9/30/18

Management

Jack Stover – Chief Executive Officer
Greg Richard – Chief Commercial Officer
Syd Finkelstein, MD – Chief Scientific Officer
Alidad Mireskandari, PhD – VP of Business Development
Jim Early – Chief Financial Officer
Sara A. Jackson, PhD – VP of Clinical Development
Glenn Gershon – SVP of Operations
Christina Narick, MD – VP of Pathology

Contact

Edison Advisors
Joe Green/Andrew Gibson
(646) 653-7030/(646) 653-7719
jgreen@edisongroup.com
agibson@edisongroup.com